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Available online 27 May 2016The evolution of pediatric solid tumors is poorly understood. There is conﬂicting evidence of intra-tumor genetic
homogeneity vs. heterogeneity (ITGH) in a small number of studies in pediatric solid tumors. A number of copy
number aberrations (CNA) are proposed as prognostic biomarkers to stratify patients, for example 1q+ inWilms
tumor (WT); current clinical trials use only one sample per tumor to proﬁle this genetic biomarker. We
multisampled 20 WT cases and assessed genome-wide allele-speciﬁc CNA and loss of heterozygosity, and in-
ferred tumor evolution, using Illumina CytoSNP12v2.1 arrays, a custom analysis pipeline, and the MEDICC algo-
rithm. We found remarkable diversity of ITGH and evolutionary trajectories inWT. 1q+ is heterogeneous in the
majority of tumors with this change, with variable evolutionary timing. We estimate that at least three samples
per tumor are needed to detect N95% of cases with 1q+. In contrast, somatic 11p15 LOH is uniformly an early
event in WT development. We ﬁnd evidence of two separate tumor origins in unilateral disease with divergent
histology, and in bilateralWT.We also show subclonal changes related to differential response to chemotherapy.
Rational trial design to include biomarkers in risk stratiﬁcation requires tumormultisampling and reliable delin-
eation of ITGH and tumor evolution.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Intra-tumor genetic heterogeneity (ITGH) has been documented in
several adult tumors. Such tumors typically evolve over longperiods be-
fore diagnosis, with most demonstrating branched evolutionary trajec-
tories (Nowell, 1976; Greaves and Maley, 2012; Gerlinger et al., 2012,
2014; de Bruin et al., 2014). However, the prevalence and relevance of
ITGH are poorly understood in pediatric solid tumors: since they carry
lower burdens of mutational changes and have evolved for shorter pe-
riods of time before diagnosis, they may be expected to show less com-
plex evolutionary histories (Vogelstein et al., 2013).
Although there are relatively few sequence mutations in pediatric
malignancies, DNA copy number aberrations (CNA) and rearrangementsh, London, United Kingdom.
. This is an open access article underare often characteristic features of these tumors. Some common CNA
have recognized prognostic signiﬁcance in pediatric tumors. For exam-
ple, in neuroblastoma,MYCN ampliﬁcation or subchromosomal genomic
gains and losses are used to stratify therapy (Schleiermacher et al.,
2011). In Wilms tumor (WT), gain of 1q (1q+) is increasingly being
proposed as a common prognostic biomarker to select patients for
more intensive treatment (Natrajan et al., 2006; Gratias et al., 2013;
Segers et al., 2013). However, these studies have relied on a single
tumor sample from each case.
Indeed, there has been limited investigation of ITGH in pediatric
solid tumors. A recent multisampling study reported genetic homoge-
neity in multi-sampled embryonal brain tumors (Remke et al., 2015).
However, a study of four pediatric small round cell tumors, with two
samples from each, reported heterogeneous CNA in three out of four tu-
mors (Mengelbier et al., 2015).
In WT, a large study showed that combined loss of heterozygosity
(LOH) of chromosomes 1p and 16q, while rare, was not only associatedthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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of the 10% of tumors from which two separate samples were assessed
(Grundy et al., 2005). In contrast, heterogeneous WTX deletion has
been reported in twomulti-sampledWTs (Wegert et al., 2009), and het-
erogeneous activation ofMYCN and inactivation of TP53 have been re-
ported in a case of bilateral WT ( Popov et al., 2013; Williams et al.,
2015).
Such variable heterogeneity complicates clinical decision making
because of a poor understanding of the evolution of pediatric tumors.
It also means that most previous studies showing prognostic signiﬁ-
cance for speciﬁc CNA did not take into account potentially signiﬁcant
ITGH. Therefore, here we assess the extent and signiﬁcance of ITGH in
a prospective study of unselected multi-sampled Wilms' tumors.
2. Methods
2.1. Samples
We obtained multiple samples from WT nephrectomy/nephron-
sparing surgery specimens at Great Ormond Street Hospital between
May 2011 and June 2013. All patients were enrolled on the SIOP WT
2001 trial (Pritchard-Jones et al., 2015), the current IMPORT study or
their parents had consented for additional tissue to be used in research
as part of the UK Children's Cancer and Leukaemia Group tissue bank.
The research reported here was approved by a national research ethics
committee. Patients received preoperative chemotherapy as per the
SIOP WT 2001 trial protocol or according to national clinical guidelines
based on this trial. Tumors were classiﬁed as previously described
(Vujanić et al., 2002). A histological section from each tissue sample
was reviewed to determine viable tumor content, and only samples
with more than 50% viable tumor (the remainder consisting of necrotic
tumor/post-chemotherapy change) were used. DNA was extracted
using standard techniques from each tumor sample, and from adjacent
non-tumorous kidney where it was available in 19 cases, and from pe-
ripheral blood lymphocytes in 3 cases.
2.2. Imaging
In two cases, different regions within the same tumor were identi-
ﬁed prospectively as distinct nodules in the same overall tumor mass
on T1- and T2-weighted MR imaging, and matched on comparison of
pre- and post-chemotherapy images. Assessed diffusion coefﬁcient
(ADC) was calculated by one observer (ØEO) as previously described
(McDonald et al., 2010).
2.3. Molecular Analyses
Illumina® HumanCytoSNP-12 v2·1 microarrays (~300,000 SNP
probes) were hybridized with 250 ng DNA per sample according to
the manufacturer's instructions. Methylation-speciﬁc multiplex liga-
tion-dependent probe ampliﬁcation (MS-MLPA) for 11p15 was carried
out as previously described (Scott et al., 2008a), using the Salsa MS-
MLPA BWS/RSS ME030-C3 probemix (MRC-Holland), and data visual-
ized in Coffalyser.NET (MRC-Holland).
2.4. Detection of Allele-Speciﬁc Copy Number Aberrations and Inference of
Tumor Evolution
Log R ratio (log2[observed intensity/reference intensity], LRR) and B-
allele frequency (BAF) were calculated using the Illumina®
GenomeStudio software for each array using default settings. LRR geno-
mic waves (Diskin et al., 2008) were detected in normal tissue samples
and corrected fromall arrays. The LRRs fromeach arraywere segmented
and copy number states were called using the ‘CGHcall’ R package (van
de Wiel et al., 2007) in Bioconductor (Gentleman et al., 2004). For each
case, the boundaries between adjacent regions were compared,smoothed and summarized between samples using the ‘CGHregions’ R
package (van de Wiel and van Wieringen, 2007) in Bioconductor
(Gentleman et al., 2004). A region was removed if it contained fewer
than 100 probes or its probe density was an outlier. The mean tumor-
speciﬁc mirrored BAF (mBAF) was calculated for each aberrant region
and copy number aberrationswere rejected if they did not showexpect-
ed allelic imbalance. Aberrant regions detectable only in the BAF (i.e.
copy number neutral LOH) were incorporated into our analysis using
a custom pipeline. Allele-speciﬁc copy number was interpreted by the
phylogenetic algorithm MEDICC (Schwarz et al., 2014) to infer clonal
evolution of samples in each case. Normal tissue samples were used to
root phylogenetic trees. Annotated code of our entire analysis pipeline
is available as a GitHub repository at: https://github.com/luslab/
multiregion-cnv-phylogenetics.
2.5. Role of the Funding Source
The study sponsors did not participate in study design, in the collec-
tion, analysis, and interpretation of data, in the writing of the report, or
in the decision to submit the paper for publication.
3. Results
3.1. Intra-Tumor Genetic Heterogeneity in Wilms Tumor Demonstrates
Unexpected Diversity
We studied 70 distinct tumor samples from 24 tumors in 20 pa-
tients (mean 3.5 samples/case, range 2–6 samples), with matched
DNA from non-tumorous kidney and/or peripheral blood leukocytes
in 19 cases. Five patients (Cases 9, 10, 16, 17, 20) had bilateral WT,
and we obtained samples from both tumors in four of them; in
Case 9, the contralateral tumor had been removed prior to the start
of our study. Patient characteristics and samples are summarized in
Table 1. We applied a custom-built pipeline to determine reproduc-
ibly genome-wide allele-speciﬁc CNA and LOH events using high-
resolution SNP arrays hybridized with genomic DNA from each sam-
ple, and automatically compare these events across samples in a
tumor. Fig. 1 shows a graphical representation of all CNA and copy
number neutral LOH (CNNLOH) events across the 70 tumor samples.
We detected most known recurrent WT CNA/LOH, including those
associated with poor outcome (Natrajan et al., 2006; Gratias et al.,
2013; Segers et al., 2013; Grundy et al., 2005). Surprisingly, 1q+
was heterogeneous in four of seven (57%) multi-sampled tumors
with this change (see below). In general, we found remarkable diver-
sity in the extent of intra-tumor CNA and CNNLOH heterogeneity,
ranging from cases with unique CNA/CNNLOH events in all or most
samples (such as Cases 1 and 15) to tumors exhibiting no CNA/
CNNLOH heterogeneity across samples. The latter either lacked so-
matic CNAs/CNNLOH (Case 12) or showed a consistent pattern of so-
matic CNAs/CNNLOH across all samples (Cases 2, 3, 6), and the single
dominant clone in each tumor showed few (0–4) CNAs/CNNLOH
events. The four patients with these homogeneous (and unilateral)
tumors were not statistically signiﬁcantly younger than the other
twelve patients with heterogeneous unilateral tumors (Welch two-
sample one-tailed t-test, t =−1.52, p = 0.08), suggesting that het-
erogeneity does not arise purely as a consequence of later age at
diagnosis.
3.2. Diverse Evolutionary Pathways inWilms Tumor: From Homogeneity to
Branched Evolution
In order to infer the evolutionary history of tumors, we generated
phylogenetic trees depicting the relationships between samples. Our
pipeline requires a minimum of four samples, and this condition was
satisﬁed in seventeen cases. In thirteen cases, all tumor samples were
from the same kidney (unilateral). We obtained a ﬂat phylogenetic
Table 1
Summary of patients and samples used in this study.
Case
number
Gender Age at
nephrectomy
(months)
Local
pathological
stage
Histological
subtype
Number of
analyzed tumor
samples
Germline DNA samples analyzed (NK:
non-tumorous kidney; PBL: peripheral blood
lymphocytes)
ADC
analysis
Additional clinical features
1 F 10 1 Stromal 2 NK, PBL No Contralateral nephrogenic rest
2 M 18 2 Mixed 3 None No Contralateral nephrogenic rest. Germline truncatingWT1mutation in exon 7
3 M 32 3 Mixed 3 PBL No Large tumor complicated by hypertensive cardiomyopathy. Surgery delayed due to
anesthetic risk and chemotherapy extended until surgery at 10 weeks due to tumor
enlargement.
4 F 58 2 Blastemal 3 NK No
5 M 48 2 Regressive 2 NK No
6 M 19 3 Mixed 3 NK No Hemihypertrophy
7 F 10 2 Mixed 3 NK No Congenital pulmonary atresia
8 M 34 2 Mixed 3 NK Yes Tetralogy of fallot
9 F 32 1 Mixed 3 NK No Developmental delay. Constitutional gain of 22q11.
10 months before this partial nephrectomy: separate nephrogenic rest in same (left)
kidney, conﬁrmed on biopsy, and contralateral (right) regressive WT (after 9 weeks
preoperative chemotherapy).
10 M 36 Right: 1
Left: 2
Right:
mixed
Left: mixed
Left: 2
Right: 1
NK (left) No Parents are ﬁrst cousins
11 F 20 1 Regressive 3 NK No
12 F 6 1 Mixed 4 NK No
13 F 27 3 Mixed 5 NK Yes Contralateral nephrogenic rest
14 M 12 1 Mixed 2 NK No Incidental diagnosis of WT during investigation of bilateral cryptorchidism. GermlineWT1
substitution in exon 9 (His405Arg)
15 M 14 2 Mixed 6 NK No
16 M 28 Right: 3
Left: 3
Right:
regressive
Left:
regressive
Right: 2
Left: 1
NK (right) No Bilateral nephron-sparing surgery with tumor at margins bilaterally
17 F 5 Right: 2
Left: 1
Right:
mixed
Left: mixed
Right: 3
Left: 2
NK (right) No
18 F 50 3 Diffuse
anaplastic
3 NK No Tumor rupture. Pulmonary metastases.
19 F 42 1 Mixed 6 NK No
20 M 29 Right: 1
Left: 1
Right:
mixed
Left:
stromal
Right: 3
Left: 2
NK (right) No Germline truncatingWT1mutation in exon 9 (associated with Denys-Drash syndrome)
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Fig. 1. Scope of intra-tumor copy number heterogeneity in 20Wilms tumor cases. Case numbers, indicated on the y-axis, are split into three groups i) homogeneous, ii) bilateral and iii)
heterogeneous. Chromosomes 1 to 22 and X are ordered on the x-axis from left to right, separated by vertical dashed lines. Cases are separated by solid black horizontal lines and samples
from each case by dashed horizontal marks at each chromosome boundary. In the bilateral group, samples from contralateral kidneys are split by horizontalmarkers either side of the plot.
Copy number states are displayed as white (expected copy number state), red (gain state), blue (loss state) and grey (expected copy number state with loss of heterozygosity).
123G.D. Cresswell et al. / EBioMedicine 9 (2016) 120–129tree, where all samples contain the same clone, in Cases 3, 6 and 12.
Cases 7 and 9 gave a linear tree, inwhich clones are derived from ‘ances-
tral’ clones sharing all prior evolutionary events. Branched evolution, in
which more than one clone contains unique events compared with a
common ancestor, was observed in the remaining seven unilateral tu-
mors (1, 4, 8, 11, 13, 15, 18, 19).
Branched evolution is particularly well demonstrated by Cases 15
and 19, with marked branching that began early in the clonal evolution
of the tumor. In Case 19 (Fig. 2), themost recent common ancestor clone
observed in sample R4 shows 1q+ and 16q−. All other tumor samples
display extra CNAs: R3 and R2 share four additional events (+13,
16p+, +20, +X) and cluster separately from R5, R1 and R6. R2 con-
tains a clone with two additional events (11q− and 13q13.1−) to R3.
Interestingly, 13q13.1 loss removes a speciﬁc region encompassing
BRCA2, after previous gain of the entire chromosome 13. R5, R1 and
R6 share a +12 event that explains the distinct branching of the sam-
ples. However, further branching is seen in these samples as R5 contains
two unique events (+6, +18), and R1 and R6 both exclusively share
four events (+8, 3p25.3−, 14q22.2–23.3−, 22q13.31−). The clone
present in R1 and R6 acquired three focal losses late in its evolution
that encompass known cancer genes such as VHL, a tumor suppressor
gene commonly mutated in clear cell renal cell carcinoma (ccRCC)
(Gnarra et al., 1994), and SIX1, a gene that was recently reported to be
recurrently mutated in WT (Wegert et al., 2015; Walz et al., 2015)(3p25.3− and 14q22.2–23.3−, respectively). Case 15 is even more di-
versiﬁed, with unique events in ﬁve of six samples (Supplementary
Fig. 1).
3.3. Genetic Markers and Evolutionary Timing
3.3.1. Chromosome 11p15 Uniparental Disomy is Consistently an Early
Event in WT Tumorigenesis
We observed 11p15 CNNLOH in 9 of 20 cases (Fig. 1). In six of these
cases, LOH also involved the entire 11p13 region, and in Case 18, it in-
volved part of the 11p13 region, including the WT1 locus; in Cases 4
and 8, 11p LOH did not involve 11p13. In all but Case 14, 11p15 CNN
LOH was detected in all tumor samples, indicating that it occurred in a
common ancestor of all observed clones in these tumors, and is thus a
consistent early event in WT tumorigenesis. The observation that
11p15 CNNLOH was a truncal event in the evolution of these WTs was
conﬁrmed by phylogenetic analysis. In Case 14, 11p15 CNNLOH was
called in just one of the two samples taken from this tumor, where it
was the only CNA observed (Fig. 1). Visual inspection of the chromo-
some 11 BAF plots for this case shows that despite not being identiﬁed
in one of the samples by our computational analysis, the event does ap-
pear to be present in a low fraction of cells (Supplementary Fig. 2).
Therefore, Case 14 does not contradict the evidence from other cases
that 11p15 CNNLOH is a consistently early event in WT tumorigenesis.
Fig. 2. Branched evolution of a multi-sampled Wilms tumor from Case 19. (A) Phylogenetic tree displaying the evolutionary relationship between the normal kidney sample (NK, green
node) and tumor samples (R1–6, red). Vertical edges are weighted by the number of copy number alterations that were acquired as the tumor evolved and the events themselves are
labelled next to the appropriate edge. Horizontal edges are not weighted and are used to separate graphically the nodes. (B) Copy number proﬁles of the normal kidney and tumor
samples. Plots display the Log R ratio on the y-axis and chromosomes 1–22 and X on the x-axis. Data are shown for every tenth SNP probe. Data points corresponding to normal
diploid copy number states are coloured grey, those representing copy number gains are in green and losses in dark red. (C) An annotated photograph of the opened nephrectomy
specimen, showing the locations of the sampled tumor and normal kidney regions.
124 G.D. Cresswell et al. / EBioMedicine 9 (2016) 120–129Since chromosome 11p15 contains a cluster of imprinted genes, we
performed MS-MLPA on the 11p15.2 locus (Scott et al., 2008a) in all
cases with 11p CNNLOH, and in all tested samples found uniparental
disomy (UPD), as indicated by hypermethylation of the H19 DMR (con-
sistent with overexpression of the IGF2 oncogene) and hypomethyla-
tion of the KvDMR, (i.e. a paternal pattern). DNA from adjacent
normal kidney was available for eight of the nine cases with 11p15
CNNLOH, and in all eight cases, there was neither 11p CNNLOH nor ab-
normal methylation, indicating that the CNNLOH and methylation ab-
normalities were somatic events in the tumor cells.
In contrast, MS-MLPA on the cases without somatic 11p15 CNNLOH
showed ﬁve cases (Cases 6, 10, 13, 17, 19)with hypermethylation of the
H19 DMR only, with normal methylation of KvDMR. In these cases, the
abnormalmethylation patternwas also present in adjacent histological-
ly normal kidney. Case 6 had known hemihypertrophy, but the other
cases had not been diagnosed with Beckwith-Wiedemann syndrome,
hemihypertrophy, abnormal growth, macroglossia, hypoglycemia or
other tumors.
3.4. Gain of Chromosome 1q Shows Variable Timing
We observed 1q+ in eight patients (40%, Fig. 3; Supplementary Fig.
3). For seven of these we had multisampled the tumors in which wedetected the change. 1q+ is present in all the tumor samples in three
of these cases (Cases 11, 15, 19). In Cases 11 and 19 the same 1q+ is
in all samples. In Case 15 there is 1q+ in all tumor samples (n = 6);
however, there are several unique CNAs that affect this chromosome
arm, thus displaying ITGH in the extent of 1q+ itself. In the remaining
four cases, 1q+ is present in one of three (Cases 4 and 9), one of two
(Case 16, right kidney tumor) and two of three (Case 20, right kidney
tumor) samples. Thus, if we had single sampled our tumors, we would
have only deﬁnitely identiﬁed three of seven tumors with 1q+; the
probability of ﬁnding 1q+ in all seven tumors with single sampling is
only 0·037. Indeed, the average probability of obtaining a negative sin-
gle sample per tumor in our set of seven multi-sampled tumors with
1q+ is 0.31 (95% conﬁdence interval is 0.08–0.54), despite 1q+ being
present in all samples obtained from three of the seven positive tumors.
The cumulative binomial distribution with p = 0.69 indicates that at
least three samples per tumor must be studied in order to ensure that
greater than 95% of tumors with 1q+ are detected.
In the four tumors which display 1q+ ITGH, 1q+ shows no prefer-
ence in evolutionary timing. In Cases 9 and 16 chromosome1q+ timing
is indistinguishable from other copy number changes present in the
tumor because samples from these tumors represent either the only
clonewith tumor-speciﬁc CNAs or have a copy number proﬁle that is in-
distinguishable from matched germline DNA. In Cases 4 and 20 1q+
Fig. 3. Chromosome 1q gain (1q+) is variably heterogeneous in eight cases. (A) Each sample is shownas a circle,ﬁlled in green if there is 1q+and inwhite if there is not. Bilateral cases are
split into contralateral samples with a horizontal black line. (B) Chromosome 1 copy number proﬁles for samples from Case 20. Log R ratios (y-axis) are shown for all chromosome 1 SNP
probes, ordered by genomic position on the x-axis. Data points are coloured green if they correspond to copynumber gains, and grey if not. Samples R1 and R4 displaywhole chromosomal
arm gains.
125G.D. Cresswell et al. / EBioMedicine 9 (2016) 120–129follows other CNAs (e.g. UPD of chromosome11p in both cases) indicat-
ing that 1q+ evolved late. In contrast, in Cases 11 and 19 1q+ is a
truncal event that may have occurred early in tumor evolution.
3.5. Rarer Biomarkers
Other WT biomarkers are difﬁcult to assess without larger patient
cohorts. Nevertheless, we observed 16q− in four tumors, three of
which are multi-sampled (Fig. 1). Of these, Cases 18 and 19 showhomogeneous 16q−, accompanied in Case 18 by homogeneous 1p−
and 4q−. In Case 13, 16q− is apparently heterogeneous, but the
change is present in the one sample that is from a tumor that probably
originated independently in the same kidney (see below); therefore, we
have no evidence to support 16q− as a heterogeneous event. Two cases
contain a LOH event that affects the TP53 locus: homogeneous 17p
CNNLOH in Case 18 and apparently heterogeneous loss of TP53 in Case
13 occurring in the single sample from the tumor with probable inde-
pendent origin. Case 18 showed diffuse anaplasia on histological
126 G.D. Cresswell et al. / EBioMedicine 9 (2016) 120–129examination, whereas Case 13 showed neither diffuse nor focal anapla-
sia or nuclear unrest. FocalMYCN gain is heterogeneous in Cases 7 and 8
and homogeneous in Cases 3 and 16.MYCN gain is germline in Case 16
(previously reported (Williams et al., 2015)).
3.6. Spatially Separated Tumors
3.6.1. Bilateral Tumors
Five cases in our dataset are bilateral WTs, and in four of these both
sides were sampled (Cases 10, 16, 17 and 20). Overall, bilateral tumors
appear genetically distinct and probably arose independently. Cases 10
and 17 provide the clearest examples of the striking differences in copy
number proﬁles between contralateral tumors. In Case 10 the only
tumor-speciﬁc CNAs in the two samples taken from the left tumor are
two focal deletions in chromosome 9, whereas the sample from the
right tumor shows 1q+, +9, +12, +20, +X, 7p− and 16q−. In
Case 17, the left tumor of Case 17 shows +7, +8, +12, +13, +16,
+17, +22 and +X, while the right tumor shows no tumor-speciﬁc
CNAs. In both these cases, the two contralateral tumors share no
tumor-speciﬁc CNAs and are not heterogeneous within the individual
kidneys. Case 16 only showed CNAs in one sample of two taken from
the right tumor, thus making the right tumor heterogeneous. The left
tumor sample of Case 16 did not have any CNAs.
Case 20 was heterogeneous within the right tumor, with 11p
CNNLOH in all three samples but 1q+ in only two samples. The left
tumor also contained 11p CNNLOH, but with a different centromeric
boundary, indicating this may have been a separate unrelated event in
the left tumor (Supplementary Fig. 2). However, we cannot formally ex-
clude the possibility that the tumors in the two kidneys developed from
a single clone with the shorter 11p CNNLOH, showing no further evolu-
tion in the left tumor and extension of 11p CNNLOH in the right kidney.
3.7. Evidence for Two Separate Tumors in the Same Mass
Case 13 presented as one tumor mass consisting of a larger middle
nodule, consisting of mixed blastemal, epithelial and stromal elements,
contiguouswith a superior nodule composed of relativelywell-differen-
tiated epithelial structures, thus showing two contrasting WT pheno-
types in the same apparent tumor. Four samples were obtained from
the middle nodule and one from the superior nodule. The samples
from the middle nodule were heterogeneous due to the presence orFig. 4. Phylogenetic analysis reveals two genetically distinctWilms tumorswithin a singlemass
kidney sample (NK, green node) and tumor samples (R1–5, red). The edges were drawn using
since their only common ancestral state corresponds to the normal kidney sample. The histo
stromal elements, whereas the superior nodule, represented by R5, is markedly different and cabsence of +2, with homogeneous +6, +8, +9, +10, +12. The sam-
ple from the superior nodule contained 16q− and 17p−. Thus, the two
nodules showed independent branching from germline DNA, suggest-
ing that they arose independently, despite appearing as one contiguous
tumor (Fig. 4).
3.7.1. Relation to Treatment Response
Case 8 also presented with a large intrarenal mass contiguouswith a
smaller nodule (Fig. 5A). Followingneoadjuvant chemotherapy, howev-
er, the smaller nodule showed a greater shrinkage (78% vs. 42%, Fig. 5B)
and increased ADC (0.71 to 1.71 vs. 0.73 to 1.32, Fig. 5C) than the main
tumor mass, indicating a better response to chemotherapy (McDonald
et al., 2010; Hales et al., 2015). Histologically, all areas of the tumor
showed a mixed histology.
We obtained one sample from the smaller nodule (R1) and two from
the larger mass (R3, R4); they show ITGH and phylogenetically, R4 rep-
resents a clonal ancestor of the other two samples. R3, also from the
larger mass, evolved an additional Xp11.23−, while the smaller nodule
developed 2q CNNLOH and aMYCN gain.
4. Discussion
Short-term outcomes in pediatric cancers are better than in adult
cancers, but relapses are often unpredictable, and most current treat-
ment protocols depend on cytotoxic agents with signiﬁcant long-term
complications (Reulen et al., 2010). There is a need to select better
those patients who need more/less intensive therapy, and to increase
the use of potentially safer targeted therapies. In WT, 1q+ is a promis-
ing genetic biomarker for such stratiﬁcation, because it is both common
and associated with a poorer outcome. Nevertheless, to date, assess-
ment of its prognostic signiﬁcance and suggested use in clinical trials
has assumed that single tumor sampling is representative and sufﬁcient.
There is emerging evidence from a small number of recent studies that
inWT and other pediatric solid tumors, a subset of cases show ITGH.We
therefore hypothesized that ITGH inWTmay involve prognostically sig-
niﬁcant CNA such as 1q+, and therefore we prospectively multi-sam-
pled a series of twenty WT cases in our center. In parallel, we
developed a custom analysis pipeline to detect reliably CNA and LOH
events, compare them across multiple samples for each tumor, and
infer evolutionary trajectories in order to provide a basis for under-
standing how ITGH arises.We found a remarkable range of evolutionaryin Case 13. The phylogenetic tree shows the evolutionary relationship between the normal
the same rules as in Fig. 2. The tree shows that sample R5 is genetically distinct from R1–4,
logy of the middle nodule, represented by R3, is triphasic, with blastemal, epithelial and
omposed exclusively of more mature epithelial elements (original magniﬁcation, ×100).
Fig. 5.Wilms tumor phylogenymirrors the differential treatment responses shown by different parts of the same tumor in Case 8. (A) Pre- and post-chemotherapy T2-weightedmagnetic
resonance (MR) images show the twomasses indicated by red (small nodule) and orange (large nodule) dashed lines. (B) Estimated tumor volumes pre- and post-treatment shows that
the small nodule (red) shrank by 78% and the large nodule shrank by 42% (orange). (C) The small nodule (red) showed a greater post-chemotherapy gain in the mean assessed diffusion
coefﬁcient (ADC) than the large nodule (orange), indicating a better response to chemotherapy. (D) A phylogenetic tree shows the genetic relationships between samples from the large
nodule (R3–4, orange) and the small nodule (R1, red). The normal kidney sample is represented by a green node (NK). The small nodule is related to the rest of the tumor, but has evolved
additional changes, including focal gain ofMYCN.
127G.D. Cresswell et al. / EBioMedicine 9 (2016) 120–129scenarios and variable ITGH inWT, including 1q+. Indeed, our data in-
dicated that single sampling misses a signiﬁcant proportion of cases
with 1q+, and we estimated that to detect more than 95% of cases
with 1q+, one would need to obtain at least three tumor samples per
case.
We also found that 1q+ does not show preference in evolutionary
timing—it may occur as an early or late event—which suggests that its
oncogenic effect is independent of other genetic changes. Therefore,
we suspect that 1q+may have a similar effect onWT outcome regard-
less of whether it is homogeneous or heterogeneous in the primary
tumor, and that current studies based on single tumor sampling may
have underestimated its prognostic signiﬁcance. Our ﬁndings clearly
imply that future clinical trials in WT must take this heterogeneity
into account and multi-sample each tumor or attempt to detect this
change in circulating tumor DNA at a level that can interrogate
subclonality.
In contrast, we ﬁnd that somatic 11p15 CNNLOH, another common
change in WT, is consistently an early event in WT tumorigenesis. Our
ﬁnding therefore builds on previous observations of somatic 11p
CNNLOH in WT precursor lesions (nephrogenic rests) (Charles et al.,
1998). 11p15 CNNLOH is associated with several other pediatric smallround cell tumors, and recently it was found as a recurrent lesion in
the vast majority of pediatric adrenocortical tumors, also occurring as
an early event preceding most point mutations (Pinto et al., 2015).
These ﬁndings suggest that 11p15 CNNLOH may represent a common
mechanism of tumorigenesis in a signiﬁcant proportion of pediatric
solid tumors, and its occurrence as an early event makes it a promising
candidate for early detection of pediatric cancer by non-invasive screen-
ing for ctDNA in blood.
In those tumors without 11p15 CNNLOH we identiﬁed a subset of
ﬁve cases with isolated hypermethylation of the H19 DMR, and this ab-
normality was also present in adjacent histologically normal kidney. In
one of these ﬁve cases, there was hemihypertrophy, whereas in the
other four cases there were no features to suggest Beckwith-
Wiedemann syndrome. This ﬁnding is in keepingwith previous reports
of mosaic hypermethylation of the H19 DMR in a signiﬁcant proportion
of normal cells in cases ofWTwith this abnormality, even in the absence
of other features of Beckwith-Wiedemann syndrome (Moulton et al.,
1994; Okamoto et al., 1997; Scott et al., 2008b). Indeed, the proportion
and distribution of non-tumor cells with this WT-predisposing
epimutation may at least in part underlie the expression and variability
of the features of Beckwith-Wiedemann syndrome.
128 G.D. Cresswell et al. / EBioMedicine 9 (2016) 120–129We have uncovered evidence of independent origins of two syn-
chronousWT not only in bilateral cases but alsowithin the same kidney
containing an intra-tumoral nodule with divergent histology.While the
presence of multicentric tumors in the same kidney is a recognized fea-
ture in 5%–10% of WT, in Case 13 the nodule with divergent histology
was contiguous with the main tumor mass. Multicentric WT may thus
be under-recognized and therefore not treated appropriately. Further-
more, under current diagnostic criteria, the relative proportions of blas-
temal, epithelial and stromal elements are used to stratify WT into low/
intermediate/high-risk categories, with an underlying assumption that
such structures are all derived from the same tumor. However, this
practice needs to be reﬁned to take into account multiple tumors, of in-
dependent origins, within the same overall mass as well as multicentric
and bilateral WT.
Our ﬁndings on rarer biomarkers are more difﬁcult to interpret in
the absence of a larger multi-sampled tumor cohort. Nevertheless, our
ﬁndings on 16q− highlight the importance of interpreting ITGH in the
context of tumor evolution: in our series, 16q− is apparently heteroge-
neous only in Case 13, but it is erroneous to interpret this as evidence of
16q− ITGH, since it is present in the one sample from the smaller nod-
ule that we showed arose independently of the remaining tumor mass.
In the case of another biomarker, MYCN gain, we were able to relate
subclonal acquisition of this change to a signiﬁcantly better response
to chemotherapy (as assessed on diffusion-weighted MR imaging be-
fore and after preoperative chemotherapy).MYCN gain may be expect-
ed to be associated with more rapid cell proliferation and therefore
greater sensitivity to cytotoxic chemotherapy, and this may explain
our ﬁnding. More generally, we have shown that it is feasible to inte-
grate phylogenetic tumor analysis with monitoring of treatment re-
sponse by imaging, provided that the imaging analysis is used as a
guide to tumor sampling, in addition to current standard histological
sampling.
Taken together, our ﬁndings inWT show unpredictable and clinical-
ly signiﬁcant genetic heterogeneity that requires tumor multisampling
for its detection, and assessment of tumor evolutionary trajectories for
its interpretation. The custom analysis pipeline that we developed for
this project may be easily applied to similar data from other multi-sam-
pled tumors, and we are also extending it to integrate single nucleotide
variants and small indels, which are typically detected in sequencing
studies. Our ﬁndings have major implications for planning biomarker
sampling strategies in future clinical trials for WT, and possibly other
pediatric solid tumors.
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